Nucleic acid biomarker and use thereof
The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
1. A method of treating a human subject harboring head and neck cancer comprising administering a treatment comprising an anti-HER3 antibody to a human subject diagnosed with head and neck cancer, wherein the head and neck cancer has progressed on at least one prior systemic therapy and heregulin (HRG) gene expression of the head and neck cancer at an mRNA level is assessed as high; wherein the mRNA level is assessed using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and identified as high if a delta Ct (dCt) value of 5.0 or less is observed from a biological sample taken from the subject diagnosed with head and neck cancer, and wherein HRG is the only gene for which gene expression at the mRNA level is assessed.
2. The method of claim 1 in which the dCt value is selected from the group consisting of 5.0, 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1, 4.0, 3.9, 3.8, 3.7, 3.6, 3.5, 3.4, 3.3, 3.2, 3.1, 3.0, 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0, −0.1, −0.2, −0.3, −0.4, −0.5, −0.6, −0.7, −0.8, −0.9, −1.0, −1.1, −1.2, −1.3, −1.4, −1.5, −1.6, −1.7, −1.8, −1.9, −2.0, −2.1, −2.2, −2.3, −2.4, −2.5, −2.6, −2.7, −2.8, −2.9, −3.0, −3.1, −3.2, −3.3, −3.4, −3.5, −3.6, −3.7, −3.8, −3.9, −4.0, −4.1, −4.2, −4.3, −4.4, −4.5, −4.6, −4.7, −4.8, −4.9, −5.0, −5.1, −5.2, −5.3, −5.4, −5.5, −5.6, −5.7, −5.8, −5.9, −6.0, −6.1, −6.2, −6.3, −6.4, −6.5, −6.6, −6.7, −6.8, −6.9, −7.0, −7.1, −7.2 and −7.3.
3. The method of claim 1 , wherein the dCt value is in a range of from about 2.7 to about 4.1.
4. The method of claim 1 , wherein the subject harbors wild-type EGFR.
5. The method of claim 1 in which the biological sample comprises a tumor sample.
6. The method of claim 5 , in which a tumor tissue or fragment thereof for or with which the HRG gene expression is assessed has been removed from the subject prior to any therapy.
7. The method of claim 1 in which the anti-HER3 antibody is selected from the group consisting of patritumab, duligotumab (MEHD-7945A), seribantumab (MNI-121), MM-111, LJM716, RG-7116, tri-specific anti-EGFR/ERBB3 zybody, and huHER3-8.
8. The method of claim 1 in which the treatment further comprises administering an anti-HER3 antibody in combination with one or more of (i) a HER inhibitor, (ii) a chemotherapy, (iii) radiation, and (iv) an other targeted agent.
9. The method of claim 8 , wherein the HER inhibitor is selected from the group consisting of trastuzumab, T-DM1, lapatinib, pertuzumab, cetuximab, panitumumab gefitinib, afatinib, dacomitinib, KD-019 and erlotinib.
10. The method of claim 8 , wherein the chemotherapy is selected from the group consisting of cisplatin, carboplatin, gemcitabine, pemetrexed, irinotecan, 5-fluoruracil, paclitaxel, docetaxel, and capecitabine.
11. The method of claim 8 , wherein the anti-HER3 antibody is administered in combination with (i) cetuximab and (ii) cisplatin or carboplatin.
12. The method of claim 11 , wherein the anti-HER3 antibody is patritumab.
13. The method of claim 1 , in which the dCt value is in a range of from about −7.3 to about 5.0.
14. The method of claim 1 , wherein the HRG gene expression is assessed using an FDA-approved test.